STOCK TITAN

State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO)

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation reported beneficial ownership of common stock of Lexeo Therapeutics Inc. in a Schedule 13G filing. State Street, through investment management and trust subsidiaries, reported beneficial ownership of 4,354,775 shares of Lexeo common stock, representing 5.5% of the outstanding class.

The filing states State Street has shared voting power over 4,276,343 shares and shared dispositive power over 4,354,775 shares, with no sole voting or dispositive power. Subsidiaries involved include SSGA Funds Management, Inc., State Street Bank and Trust Company, State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 4,354,775 shares Common stock of Lexeo Therapeutics beneficially owned by State Street Corporation
Percent of class 5.5% Percentage of Lexeo Therapeutics common stock class reported as beneficially owned
Shared voting power 4,276,343 shares Shares of Lexeo common stock over which State Street has shared voting power
Shared dispositive power 4,354,775 shares Shares of Lexeo common stock over which State Street has shared dispositive power
Sole voting power 0 shares Lexeo common shares over which State Street has sole voting power
Sole dispositive power 0 shares Lexeo common shares over which State Street has sole dispositive power
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 4354775.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 4,276,343.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 4,354,775.00"
Schedule 13G regulatory
"has filed this schedule, pursuant to (ii)(G), so indicate under Item 3(g)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
parent holding company financial
"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of Lexeo Therapeutics (LXEO) does State Street Corporation own?

State Street Corporation reported beneficial ownership of 5.5% of Lexeo Therapeutics’ common stock, representing 4,354,775 shares as disclosed in its Schedule 13G filing.

How many Lexeo Therapeutics (LXEO) shares does State Street control voting for?

State Street reported shared voting power over 4,276,343 shares of Lexeo Therapeutics common stock and no sole voting power in its Schedule 13G.

What is the total number of Lexeo Therapeutics (LXEO) shares State Street can dispose of?

State Street Corporation reported shared dispositive power over 4,354,775 shares of Lexeo Therapeutics common stock and no sole dispositive power over any shares.

Which State Street subsidiaries are involved in holding Lexeo Therapeutics (LXEO) shares?

The filing identifies SSGA Funds Management, Inc., State Street Bank and Trust Company, State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as relevant subsidiaries.

Is any other person reported to have more than 5% interest in Lexeo (LXEO) via State Street’s holdings?

The Schedule 13G states “NOT APPLICABLE” for ownership of more than 5 percent on behalf of another person, indicating no such additional person is identified in this filing.





52886X107

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:08/07/2026